trial

Characterization of High-Level Cognitive Impairments in Patients With Neuropsychiatric Disorders

NCTId NCT07295652
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 600 (estimated)
Sponsored by Centre Hospitalier St Anne
Primary completion 2039-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
600 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2024-03-12
Primary completion
2039-03
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Cognitive assessmentBrain MRI (optional)Electroencephalography (optional)Magnetoencephalography (optional)

Sponsors

Centre Hospitalier St AnneLead Sponsor
Paris Brain Institute (ICM)Collaborator

Investigators

1
Pierre BOURDILLON, DrPrincipal Investigator

Sites

3 total
Paris, FranceParis, FranceParis, France

Facts & assertions

4 sourced
Enrollment
600
Phase
NA
Primary Completion Date
2039-03
Status
RECRUITING
relationships
The graph out of here
drug
Cognitive assessment
drug
Brain MRI (optional)
drug
Electroencephalography (optional)
drug
Magnetoencephalography (optional)
drug
lead_sponsor
Centre Hospitalier St Anne
company
collaborator
Paris Brain Institute (ICM)
company
indication
Bipolar Disorder
indication
Depressive Disorder
indication
Neurologic Disorders
indication
investigator
Pierre BOURDILLON, Dr
person